RET and non-small cell lung carcinoma: The LIBRETTO-001 trial, a Phase 1/2, single-arm, open-label study of selpercatinib for RET fusion-positive NSCLC patients, reported an 84% objective response rate (ORR), with 6% of patients achieving CR, a median response duration of 20.2 months, and a median PFS of 22.0 months.